Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury  by Simons, Jacob L. et al.
Kidney International, Vol. 46 (1994), pp. 396—404
Modulation of glomerular hypertension defines susceptibility to
progressive glomerular injury
JACOB L. SIM0Ns, ABRAHAM P. PRovoosT, SHARON ANDERSON, HELMUT G. RENNKE, JULIA L. TROY,
and BARRY M. BRENNER
Renal Division and Department of Pathology, Brigham and Women's Hospital, The Harvard Center for The Study of Kidney Diseases, Harvard Medical
Schoo4 Boston, Massachusetts, USA and Department of Pediatric Surgery, Erasmus Universily, Rotterdam, The Netherlands
Modulation of glomerular hypertension defines susceptibility to pro-
gressive glomerular injury. The fawn-hooded rat constitutes a spontane-
ous model for chronic renal failure with early systemic and glomerular
hypertension, proteinuria (UV) and high susceptibility to development of
focal and segmental glomerular sclerosis (FGS). It has been argued that
uninephrectomy (UNX) accelerates the development of glomerular injury
by aggravation of glomerular hypertension and by an independent effect to
promote glomerular enlargement. The present study was performed to
further delineate the importance of these parameters for the development
of FGS. At the age of eight weeks male rats were UNX and randomly
assigned to either control (CON), enalapril (ENA) or Nvnitro L-arginine
methyl ester (NAME) treatment. In all groups glomerular hemodynamic
studies were performed four weeks post-UNX. Systemic blood pressure
and U,V were monitored for 4 to 12 weeks post-UNX. Kidneys were then
prepared for morphologic study. ENA treatment achieved control of both
systemic and glomerular hypertension, maintenance of glomerular hyper-
filtration and hyperperfusion, increased ultrafiltration coefficient(K1), and
long-term protection against U,V and FGS. NAME rats showed aggra-
vation of both systemic and glomerular hypertension, decreased renal
perfusion and filtration with reduced Kf, and high filtration fraction. The
incidence of FGS in NAME and CON groups was similar at 8 and 12
weeks post-UNX, respectively. Glomerular enlargement was present in
CON and ENA rats, but did not correlate with injury, while glomerular
tuft size was lowest in NAME rats, which displayed prominent glomerular
injury. Systemic blood pressure correlated strongly with glomerular cap-
illary pressure. We conclude that systemic and glomerular hypertension
govern the development of UV and FGS. Renal protection with convert-
ing enzyme inhibition is achieved by controlling glomerular hypertension
in this highly susceptible model.
Nephron function loss, from any cause, is followed by compen-
satory glomerular hemodynamic and structural adaptations. Over
time these changes are believed to be maladaptive and result in
further deterioration of renal excretory function [1]. In rat models
of renal injury associated with permanent nephron loss, high
glomerular capillary hydraulic pressure was found to constitute a
major driving force for continuous glomerular injury with result-
ing focal and segmental glomerular sclerosis (FGS) and progres-
sive chronic renal failure (CRF) [2—4]. Amelioration of the
glomerular hypertensive state resulted in long term protection
against glomerular injury [3, 5], even when initial glomerular
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damage has already occurred [6]. The beneficial effect of angio-
tensin I converting enzyme inhibitors (ACEI) to achieve renal
protection in these studies has been attributed to the specific
property of this class of drug to reduce glomerular capillary
hypertension [3, 5, 6]. This hemodynamic theory on progressive
renal disease has been reviewed recently [7j.
It has been proposed that glomerular hypertrophy, expressed as
an increase in glomerular tuft size in response to renal injury or
ablation predisposes to further glomerular malfunction over the
long-term. This may occur as a result of increased glomerular
capillary diameter with subsequent altered wall tension, according
to the LaPlace law, or from glomerular pressure effects on
glomerular cell subpopulations or matrix [8—10].
The fawn-hooded (FH) rat is a spontaneous model for CRF, as
these animals develop the major stigmata of renal disease early in
life. These include moderate systemic hypertension, proteinuria
(UV) and FGS [11, 12]. Sclerosis and UV progress and animals
eventually die due to uremia at a relatively young age. In previous
studies we detected the early occurrence of glomerular capillary
hypertension and hyperfiltration in these animals, and were able
to predict the development of FGS according to the level of
glomerular capillary hydraulic pressure (PGC) in two inbred
substrains of FH rats [13]. For inbreeding, these rats were selected
based upon difference in awake tail-cuff systolic blood pressure
(SBP) level. Rats with highest values for SBPtC were designated
FHH, and those with lowest, FHL. FHH rats also exhibit the
highest values for U,V, GC,and fastest development of FGS and
CRF, as compared to FHL [12, 13]. In the current study we
focused our interest on this FHH substrain.
We previously reported on the marked acceleration of the
development of proteinuria and CRF in FHH rats after unine-
phrectomy (UNX). The high susceptibility of FHH rats to UNX
was thought to be related to further increases in GC [14]. In that
study, a specific role for changes in glomerular capillary tuft size
as an independent risk factor for accelerated CRF could not be
fully assessed. In the present study we further investigated and
delineated the pathophysiological properties of glomerular hemo-
dynamic and morphologic changes in progressive CRF. We
therefore modulated systemic blood pressure (BP) in UNX FHH
rats with the use of either ACEI or nitric oxide (NO) synthase
inhibition. Administration of ACEI in experimental models of
renal disease generally results in lowering of systemic BP and P0,
and protection from renal damage [2, 5, 6]. On the other hand,
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NO synthase inhibition induces systemic and glomerular hyper-
tension with subsequent FGS [15, 16]. With the use of these
pharmacological interventions we modulated systemic BP and
studied renal hemodynamics, function and morphology.
Methods
Animals
Forty-nine male FHH rats entered the study and were UNX at
eight weeks of age, and were then randomly assigned to one of
three groups. Control (CON) rats were untreated. A second
group received enalapril (ENA) (Merck Sharp & Dohme, West
Point, Pennsylvania, USA) 250 mg/liter and a third group N"-
nitro L-argininemethyl ester (NAME) (Sigma Chemical Co., St.
Louis, Missouri, USA) 50 mg/liter, both administered in the
drinking water. Half the rats in each group underwent whole
kidney and glomerular micropuncture hemodynamic studies four
weeks post-UNX. The remainder of each group was followed for
long-term functional and morphologic assessment up to 12 weeks.
Preliminaiy studies revealed that NAME rats would not survive
for these 12 weeks, and accordingly were sacrificed earlier, at
eight weeks post-UNX. Rats were fed ad libitum with standard rat
chow (24% protein) and received tap water with added drugs as
indicated up to the time of micropuncture experiment or kidney
perfusion.
Long-term functional studies
Body weight, awake systolic blood pressure (SBPtC) and urinary
protein excretion (UV) were determined before UNX and every
four weeks thereafter to time of kidney perfusion. SBPtC was
measured by tail-cuff plethysmography in awake restrained ani-
mals. Urine was collected for 24 hours from individual rats for
estimation of UV. Urinary protein concentration was measured
colorimetrically by precipitation with 3% sulfosalicylic acid.
Micropuncture
Rats were prepared and studies performed in the standard
fashion for micropuncture [3]. Rats were anesthetized with mac-
tin (100 mg/kg body wt i.p.) and placed on a temperature-
regulated micropuncture table. After tracheostomy, a left femoral
artery catheter (PE-50) was inserted to simultaneously and intra-
arterially monitor experimental systolic (SBPe)and mean arterial(MAP) blood pressure, and to obtain blood samples. After
collecting a baseline arterial blood sample, the right jugular vein
was cannulated (PE-50) for infusion of plasma and solutes. For
preserving the euvolemic state, isoncotic rat plasma was infused
i.v. at a rate of 0.1 mI/mm to a total amount equal to 1% of body
wt, and then continued at a rate of 0.58 mi/hr for the remainder of
the experiment to maintain a stable hematocrit (Hct). Inulin (5
g/dl in 0.9% NaCI) and para-aminohippuric acid (PAH) (0.4 g/dl
in 0.9% NaC1) were infused i.v. at a rate of 1.2 ml/hr. The kidney
was exposed and suspended with its surface illuminated and
bathed in 0.9% NaCI. The ureter was cannulated (PE-10/PE-50).
Micropuncture was started 60 minutes after completion of the fast
plasma infusion.
For calculation of single nephron (SN) GFR, exactly timed
samples of fluid were collected from superficial proximal tubules
for determination of flow rate and inulin concentration. Efferent
arteriolar blood samples were obtained for determination of
protein concentration (CE). Coincident with these collections and
the hydraulic pressure measurements, femoral arterial blood
samples were obtained for determination of Hct and plasma
concentrations of inulin, PAH and total protein, and 10 to 20
minute urine collections were obtained for determination of
urinary flow rate, inulin and PAH concentrations. These measure-
ments permitted calculation of GFR, effective renal plasma flow
(ERPF), filtration fraction (FF), effective renal blood flow
(ERBF), and whole kidney renal vascular resistance (RVR) by
standard formulae.
Time-averaged hydraulic pressures were measured in efferent
arterioles (PE) and in superficial proximal tubules under free flow
(PT)and stop-flow (PSF) conditions [17] with a continuous record-
ing, servo-null micropipette transducer system (Instrumentation
for Physiology and Medicine, San Diego, California, USA; Model
5A). Mean glomerular capillary hydraulic pressure (P0) was
calculated as: GC = SF + [17]. Coiloid osmotic pressure of
plasma entering (irA) and leaving (TE) glomerular capillaries was
estimated from values for protein concentration in femoral arte-
rial (CA) and efferent (CE) arteriolar plasma, and permitted
calculation of single nephron filtration fraction (SNFF) [18].
Glomerular capillary ultrafiltration coefficient (I(f), afferent and
efferent arteriolar resistances (RA and RE) and glomerular cap-
illary plasma flow rate (QA) were calculated using equations
described previously [l8liMean transcapillary hydraulic pressure
(P) was computed as: z.P = P0 —
The amount of protein excreted in the urine relative to the
GFR (mg/liter) was calculated as: (UV)/(GFR. 1.44). The 24
hour UV, determined a few days before the micropuncture study
was used in these calculations,
Renal morphology
At end of follow-up, kidneys were perfusion-fixed at SBPC for
two to three minutes with 1.25% glutaraldehyde in 0.1 M cac-
odylate buffer (pH 7.4). Kidney weight was noted. Two midcoro-
nal slices were processed for light microscopy. Plastic sections (2
pm) were stained with Toluidine blue to obtain micrographs of
representative glomeruli from each treatment group. Paraffin
sections (3 jim) stained with hematoxylin and eosin, and periodic
acid-Schiff reagent were used to assess the frequency of FGS by
counting all glomerular profiles on two coronal sections. FGS
lesions were defined as glomeruli with segmental or global
collapse of capillaries, with or without associated hyalin deposi-
tion and adhesion of the tuft to Bowman's capsule. Completely
collapsed glomeruli were excluded. The extent of FGS was
expressed as the percentage of affected glomeruli of the total
number of glomeruii counted.
To determine the average glomerular tuft volume (VG) for each
kidney, the mean glomerular random cross-sectional area (AG)
was measured on at least 50 glomerular tuft profiles by point
counting at a final magnification of 200>< using a 361-point ocular
grid covering a 369,664 jim2 microscopic field. Grossly damaged
glomeruli were excluded. VG was then calculated as VG = (f3/k)
(AQ)3"2, where f3 = 1.38 is the shape coefficient for spheres and k
= 1.1 is a size distribution coefficient [19].
Analytical
The volume of fluid collected from individual proximal tubules
was estimated from the length of the fluid column in a constant
bore capillary of known internal diameter. The tubule fluid inulin
concentration was measured by a micro-fluorescence method [20].
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Inulin concentrations in plasma and urine were measured using a
macro-anthrone method [21]. PAH concentrations in plasma and
urine were measured by the method of Chasis et al [22]. Protein
concentrations in efferent arteriolar and femoral arterial blood
plasmas were determined using a fluorometric method [23].
Statistical
Values were compared by one way analysis of variance with the
Scheffe's F-test for multiple comparisons. Statistical significance
was defined asP < 0.05. All values represent means SEM. Linear
regression analysis was performed for correlation between GC
and MAP, both obtained at the time of micropuncture.
Results
Functional studies
Long-term values for SBPtC and U,V are summarized in
Figures 1 and 2. Before UNX all animals showed similar levels for
both SBPtC and UV. After UNX and initiation of therapy, control
animals exhibited a moderate increase in SBPC over time, which
was similar to that previously found in intact two-kidney FHH rats
at corresponding ages [12, 14]. ENA treated animals exhibited
control of systemic hypertension over the duration of the study,
with values for SBPtC in the normotensive range. Animals in the
NAME group exhibited further elevation of SBP, with values of
approximately 200 mm Hg.
As shown in Figure 2, proteinuria was increased in both CON
and NAME groups, whereas ENA animals showed minimal U,V
throughout the duration of the study. UV in these ENA rats was
also lower than that generally observed in two-kidney FHH rats at
similar ages [12].
Systemic and renal hemodynamic parameters
Values for systemic and renal hemodynamic parameters at four
weeks post-UNX are summarized in Tables 1 and 2. Compared to
CON rats, values for SBPIC, SBPe, and MAP were reduced to
normotensive levels in ENA treated rats, while they were further
increased in the NAME group (Table 1). Hct was significantly
higher in NAME treated rats as compared to the other groups.
Despite the differences in BP between CON and ENA treated
rats, GFR, ERPF, and ERBF were not significantly different. On
the other hand, the severely hypertensive NAME rats showed a
significant decrease in GFR, ERPF, and ERBF resulting in a
marked increase in FF as compared to CON and ENA. Compared
to CON rats, UV and UVIGFR were reduced in ENA rats.
NAME treated animals exhibited a similar level of U,V as CON
rats, but when corrected for GFR, protein excretion was signifi-
cantly increased (Table 1).
The differences in whole kidney hemodynamics were also
present at the single nephron level (Table 2). The levels of
SNGFR, QA, and SNFF were not significantly different between
CON and ENA treated rats. Values for CA and C and thus A
and irE were also comparable. Compared to the high hydraulic
pressures obtained in oN rats, ENA treatment resulted in a
significant reduction of P, Gc and zP. Absolute values for GC
in the ENA rats were comparable with those reported for normal
euvolemic two-kidney Munich-Wistar (MW) rats, as determined
with direct and indirect stop-flow techniques, and for other rat
strains measured with stop-flow only [24]. In contrast, NAME rats
showed significantly lower levels of SNGFR and °A' and an
increase in SNFF as compared to CON and ENA rats. However,
NAME rats_had markedly increased values for SF, Gc and P.
Values for GC in ENA rats were on average 12 mm Hg lower
than in CON rats, while these values in NAME rats were on
average 14 mm Hg higher than in the CON animals. Values for
RA, RE and RT were only numerically lower in ENA animals as
compared to CON rats. Values for RT were increased, with RA
and R increased proportionally, in NAME rats as compared to
CON and ENA rats.
As depicted in Figure 3, a highly significant linear correlation
was found between MAP and GC (N = 26, r2 = 0.827, P < 0.001).
The regression equation: GC = 0.33 MAP + 25.0 indicates that
for each mm Hg increase in MAP, increases by 0.33 mm Hg.
Filtration pressure disequilibrium (1rEILP < 1) was present in
all experimental animals and permitted calculation of unique
values for Kf. It is clear that in ENA treated rats, with a reduced
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Fig. 1. Systolic blood pressure (SBP) in awake rats over long-term. Symbols
are: (S 5) CON (N = 7); (V----V) ENA (N = 9); (A----A) NAME (N
7); * P < 0.05 vs. CON; (A) P < 0.05 vs. NAME.
250
200
150
. 100
U)
0
50
0
—2 0 2 4 6 8 10 12 14
Time, weeks after UNX
Fig. 2. Urinaiy protein excretion (UV) over long-term. Symbols are:(S •) CON (N = 7); (V----Y) ENA (N = 9); (A----A) NAME (N =
7); * P < 0.05 vs. CON; (A) P < 0.05 vs. NAME.
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Table 1. Summary whole body and kidney function parameters in rats used for micropuncture studies at 4 weeks post-UNX
N
SBP1, SBPe Hct
%
GFR ERPF
mm Hg mi/mm
CON 9 169 3 161 3 129 2 45 1 1.98 0.12 6.89 0.31
ENA 8 120 4 118 2 96 3 45 1 1.86 0.18 6.42 0.51
NAME 9 219 6ab 199 6ab 168 6' 50 i 1.05 0.i4 3.05 066ab
FF
ERBF
ml!min
RVR
mm Hg! (mi/mm)
U,V
mg/24 hr
U0V/GFR
mg/liter
CON 0.29 0.02 12.68 0.5 10.4 0.5 57 11 20.1 3.7
ENA 0.29 0.01 11.6 1.0 8.6 0.6 18 2 7.0 0.7
NAME 0.38 0.02w' 5.9 i.v" 36.0 59ab 52 7' 41.3 87ab
Values are means SEM. Abbreviations are: SBPC, awake systolic blood pressure measured by tail-cuff; SBPC, direct systolic blood pressure during
micropuncture experiment; MAP, mean arterial pressure during micropuncture experiment; Hct, hematocrit; GFR, glomerular filtration rate; ERPF,
effective renal plasma flow rate; FF, filtration fraction; ERBF, effective renal blood flow rate; RVR, whole kidney renal vascular resistance; U,V, urinary
protein excretion during 24 hours; U0V/GFR, protein excretion corrected for the amount of glomerular filtrate.
a p < 0.05 vs. CON
b P < 0.05 vs. ENA
Table 2. Summary glomerular hemodynamics at 4 weeks post-UNX
N
SNGFR
ni/mm SNFF
CA CE A E
mm Hgmg/mI
CON
ENA
NAME
9
8
9
89.6 5.3
87.1 5.1
65.9 5.8a
0.30 0.01
0.29 0.01
0.38 0.o2'
5.2 0.1
5.6 0.1
5.3 0.1
7.5 0.2
7.8 0.2
8.7 0.3a
16 1
18 1
17 1
29 1
31 137 2
SF GC T
mm Hg
1E Kf
nl/(s mm Hg)
QA
nI/mm
CON
ENA
NAME
51 137 ia
64 2ab
67 1
55 ia81 2
11 112 111 1
56 144 ia
70 2ab
13 1
14 110 l'
0.044 0.002
0.076 O.OO3
0.026 02ab
296 17
304 22
181 24ab
RA RE
X 1O° dyn . seccm5
RT
CON
ENA
NAME
0.94 0.08
0.62 0.06
2.35 045ab
0.98 0.16
0.74 0.07
2.37 035ab
1.92 0.12
1.35 0.11
4.71 0•77ab
All values are means SEM Abbreviations are: SNGFR, single nephron glomerular filtration rate; SNFF, single nephron filtration fraction; CA,
afferent arteriolar.protein concentration; CE, efferent arteriolar protein concentration; ITA, afferent arteriolar oncotic pressure; ITE, efferentarteriolar
oncotic pressure; SF, mean stop-flow pressure; P0, mean glomerular capillary hydraulic pressure; T' mean tubular hydraulic pressure; P, mean
glomerular transcapillary hydraulic pressure difference; E, mean efferent arteriolar hydraulic pressure; Kf, glomerular capillary ultrafiltration
coefficient; QA, initial glomerular capillary plasma flow rate; RA, afferent arteriolar resistance; RE, efferent arteriolar resistance; RT, total arteriolar
resistance (RA + RE).
ap < 0.05 vs. CON
b P < 0.05 vs. ENA
GC, a high SNGFR could only be maintained by a significant
increase in Kf as compared to CON rats. In contrast, NAME
treatment resulted in a marked reduction in Kf.
Morphology
Micrographs of representative glomeruli from each of the three
treatment groups are given in Figure 4. Glomeruli from CON
(Fig. 4a, b) and NAME (Fig. 4e, f) at 12 and 8 weeks post-UNX,
respectively, show the typical features of FGS with segmental
mesangial expansion, tuft adhesions, and sclerosis. In contrast,
glomeruli from ENA treated rats still show normal glomerular
morphology (Fig. 4c, d) at 12 weeks post-UNX.
The morphometric data are summarized in Table 3. Values for
body weight were similar in CON and ENA groups at 12 weeks
post-UNX, and higher than those for NAME rats at eight weeks
post-UNX. Values for left kidney weight (LKW) were highest in
CON rats, whereas values for LKW in ENA and NAME groups
were comparable. Glomerular tuft size measurements revealed
similar values for G in CON and ENA groups, although those
values far exceed VG values in normal two-kidney FHH rats at
comparable age [13, 14]. VG was significantly lower in NAME rats
at eight weeks post-UNX compared to CON or ENA at 12 weeks
post-UNX. Values for VG in NAME rats are very similar to those
reported earlier in normal two-kidney FHH rats studied four
weeks after sham operation at age 12 weeks, and in intact
two-kidney FHH rats at age 8 and 16 weeks [13, 14]. Nevertheless,
NAME rats had a similar incidence of FGS as CON rats studied
at 12 weeks post-UNX. ENA rats at 12 weeks post-UNX showed
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N
Left kidney
Body wt wt
g
v0
106 pm3
FGS
%
CON 7 352 6 2.90 0.11 2.52 0.12 55.5 7.8
ENA 9 338 12 2.22 O.1P 2.44 0.12 2.1 0.4k'
NAME 7 232 15w' 2.23 0.16 1.76 011ab 59.1 5•9F,
Parameters were estimated at 8 weeks post-UNX in NAME rats and at
12 weeks post-UNX in CON and ENA rats. All values are means SEM.
Abbreviations are: VG, mean glomerular tuft volume; FGS, percentage of
glomeruli with focal and segmental glomerular sclerosis.
a P < 0.05 vs. CON
b P < 0.05 vs. ENA
80 100 120 140 160 180 200
MAP, mm Hg
Fig. 3. Correlation between mean glomerular capillaiy pressure (PGC) and
mean arterial pressure (MAP) at the time of micropuncture. Symbols are:() CON; (V) ENA; (A) NAME.
minimal FGS, with global preservation of the glomerular archi-
tecture, as in young two-kidney FHH rats [13].
Discussion
The results of the present study indicate that intraglomerular
capillary pressure is an important factor in the origin of glomer-
ular injury and sclerosis in this strain. In UNX FHH, with high
levels of glomerular hyperfiltration and hypertension in addition
to glomerular enlargement, _we observed that treatment with
ACE! prevented the rise of P0c but not in glomerular size and
abolished the development of renal damage. In contrast, NAME
treatment which lowe!ed values for SNGFR and V0, but caused
a further elevation in P0, did not reduce glomerular damage. On
the contrary, FGS 8 weeks after UNX in NAME rats was as severe
as 12 weeks after UNX in control animals. The values for P0 in
ENA rats were even lower than those reported by us for young
adult two-kidney FHH rats which develop severe proteinuria and
early glomerular sclerosis [13], and were similar to values found
for normal Munich-Wistar (MW) rats and other strains [24].
Furthermore, animal models with high resistance to progressive
glomerular injury such as the young two-kidney spontaneously
hypertensive rat (SHR) and the UNX Wistar-Kyoto (WKY), rat
have comparable levels for POC as the ENA group in the current
study [25].
Induction of a remnant kidney state (5/6 nephrectomy) or
simple UNX causes a rise in P0, SNGFR and V0 and results in
proteinuria and accelerated glomerular injury [2, 14]. Glomerular
size increases more than threefold after 5/6 nephrectomy [26].
Recently, we reported the short- and long-term events occurring
after UNX in FHH rats [14]. We found that both glomerular
hemodynamic alterations and glomerular enlargement were asso-
ciated with the accelerated development of glomerular injury.
Similar glomerular size changes after UNX in random-bred
fawn-hooded rats were reported by Westenend et al [27]. Another
study by these investigators revealed that ACEI therapy in intact
adult rats of this random-bred fawn-hooded strain arrested the
progression of glomerular injury and systemic hypertension. Al-
though V0 increased in both control and ACEI treated animals
over the seven month follow-up period, such changes were
without pathogenic significance in ACE! treated rats [281. Micro-
circulatory studies were not performed in these two-kidney ani-
mals, but whole kidney vasodilation and reduced urinary protein
excretion were noted in ACEI treated rats. Thus, it is likely that
ACEI treatment not only reduced systemic blood pressure, but
reduced GC as well.
Yoshida et at [9] suggested that glomerular growth is an
independent risk factor for progressive glomerular injury, and that
the protective effect of ACEI is mainly due to its effect to limit
glomerular enlargement. This hypothesis is not supported by our
data. Glomerular growth, present in intact random-bred [28] and
UNX FHH (current study) fawn-hooded rats treated with ACEI,
did not result in glomerular damage. Shrinkage of glomeruli in
CON rats in the present study is unlikely, since values for V0 in
this group at 12 weeks after UNX were slightly higher than the
observed value in 12-week-old UNX FHH at four weeks after
ablation [14]. A difference in glomerular size between control and
ACEI treated animals with reduced renal mass has been reported
rarely. In Table 4 data are summarized from several other renal
ablation studies in which glomerular hemodynamic and morpho-
logic responses to extrinsic modulation of angiotensin II (Ang II)
activity on progressive glomerular sclerosis were assessed. When
Ang II formation is chronically inhibited with ACEI or when its
receptors are blocked in such models, glomerular hypertension is
controlled while glomerular hyperfiltration and enlargement are
usually unaffected [3, 6, 29, 30]. Invariably, animals are protected
for glomerular injury and proteinuria. !n contrast, when Ang II
activity is increased by chronic infusion, P0, proteinuria and FGS
are further elevated [10] despite no additional change in glomer-
ular size.
The value for VG found in NAME treated rats was similar to
those previously reported for intact FHH rats at comparable ages
[13, 14], and smaller than the mean value seen in UNX rats
followed for four weeks [14]. The incidence of FGS in NAME rats
eight weeks after UNX was similar to that of CON rats after 12
weeks of follow-up. This probably reflects faster progression of
glomerular damage in NAME animals. Thus, while glomerular
size in NAME treated rats was limited, glomerular injury devel-
oped early. Of note in this respect is the possibility that the higher
PGC in NAME rats may have offset any limitation in glomerular
size. Therefore, our data indicate that, although a role for
glomerular size changes in progressive glomerular injury in UNX
FHH rats cannot be completely excluded, the data do indicate
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Fig. 4. Representative light micrographs at low and high power magnification of glomendi in kidneys taken from CON (A, B), and ENA (C, D) rats, at 12
weeks after unilateral nephrectomy, and from NAME (E F) rats at 8 weeks post-UNX. Plastic sections, 2 .tm thick were stained with Toluidine Blue. The
magnification is 120x for A, C and E, and 350X for B, D and F.
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Table 4. Effects of chronic angiotensin II modulation on glomerular hemodynamics and structure after renal ablation
Model + modulation
SNGFR
nI/mm
I'GC
mm Hg
K1
nl/(sec mm Hg)
V0
iO j.un3
FGS
% Reference
Ang II inhibition
Rm-MW 93 8 69 2 0.05 0.01 2.1 0.1 21 3 [3]
Rm-MW + ACEI 82 7 54 ia 0.09 0.02a 1.7 o.la 6 2 [3]
Rm-MW 182 37 65 2 0.12 0.03 2.0 0.1 18 [5]
Rm-MW + ACE! 211 17 54 3 0.26 0.04a 2.0 0.2 9 [5]
Rm-MW 118 4 65 1 0.08 0.01 4.0 0.2 41 3 [29]
Rm-MW + ACE! 112 6 54 2 0.14 0.03 3.6 0.2 9 ia [29]
Rm-MW + LOS 107 6 56 2 0.11 0.01 3.8 0.2 9 ia [29]
UNX-DM-MW 91 7 60 1 0.07 0.01 2.3 0.1 20 3 [30]
UNX-DM-MW + ACE! 90 10 49 2 0.15 0.04a 2.4 0.3 5 ia [30]
UNX-FHH 90 5 67 1 0.04 0.01 2.5 0.1 56 8 This study
UNX-FHH + ACE! 87 5 55 ia 0.08 0.Ola 2.4 0.1 2 ia This study
Ang II activation
UNX-MW 76±6 56±3
UNX-MW + Ang II 72 10 69 6 0.08 0.01 2.4 0.2 1 1 [10]0.05 0.Ola 2.2 0.2 18 ioa [10]
Summa.!y of measurements of single nephron glomerular filtration rate (SNGFR), ultrafiltration coefficient (K1), mean glomerular capillary hydraulic
pressure (P0), mean glomerular tuft volume (V0), and glomerular injury (FGS) in studies assessing the effects of angiotensin II modulation in renal ablation
models. All values are means SEM, except [10] providing means SD. Abbreviations are: UNX, uninephrectomy; Rm, remnant after 5/6 nephrectomy; MW,
Munich-Wistar; FHH, fawn-hooded; ACE!, chronic angiotensin I converting enzyme inhibition; Mg II, chronic angiotensin II infusion; LOS, chronic
angiotensin II receptor blockade with losartan; DM, diabetes mellitus (streptozotocin).
a P < 0.05 vs. untreated
that glomerular hypertrophy alone in the absence of glomerular
hypertension does not confer risk.
The importance of glomerular hypertension as the driving force
for proteinuria in experimental renal disease has been established
in several experiments [31, 32]. Hyperfiltration and hyperperfu-
sion are maintained in ACEI treated animals (Table 4), indicating
that such alterations do not lead to glomerular injury in the
absence of glomerular hypertension. The data on iç in Table 4
and NAME treated rats in the current study also provide further
evidence that increased hydraulic permeability is associated with
preservation of glomerular structure and function over the long-
term. Furthermore, this finding supports the observation that rat
strains which respond to renal mass reduction with an increase in
K1, while maintaining a normal Pc, are protected against pro-
gressive glomerular injury. The WKY rat is an example of such a
response. It has been reported that the UNX [25] and remnant
WKY [33] show compensatory increases in SNGFR, which are
mainly due to an increase in Ic, since P0c remains at a normal
level. Both models of renal ablation in WKY rats are remarkably
resistant to development of FGS [25, 33].
Although still debated, Ang II is thought to act preferentially on
the contraction of the post-glomerular vessels in normal circum-
stances [34—36]. These Ang II actions on the glomerular circula-
tion tend to become more apparent when renal mass is reduced
[231]. However, in chronic ACEI treated MW rats with reduced
renal mass, a reduction of both RA and RE has been described [3,
5], whereas in chronic Ang II infusion, both resistances are
enhanced [10]. Also in ACEI treated rats in our present study,
arteriolar resistances in pre- and postglomerular vessels tended to
be lower, but no selective decrease of R was found. We think
that the reduction of RA may represent the autoregulatoiy
response to the fall in systemic BP, through a myogenic reflex, in
order to maintain glomerular filtration [37]. Thus the selective
action of Ang II on R could not be identified in this UNX animal
model. This possibility is supported by the observation that in
response to a non-pressor dose of Ang II administered via the
renal artery, RA fails to increase, but RE and Gc do [38].
Furthermore, when systemic BP is kept unaltered during acute
Ang II antagonist infusion, RE and Gc are selectively reduced
[32]. It is obvious, however, that we cannot exclude other mech-
anisms such as a structural change in the resistance vessels over
long-term. The contractile properties of the mesangium are
affected by Ang II, and thus may regulate KSn vivo [10, 32, 34, 36].
Since the reduction of both RA and RE was only numerical with
ACEI, but K1 was greatly increased, it is suggested that ACEI and
thus Ang II in FHH rats act on K1 to regulate glomerular
ultrafiltration. In addition, the current observations do not ex-
clude the possibility that actions of ACEI are not limited to effects
on Ang II alone, but also relate to effects on other vasoactive
substances [39].
Animals treated with the NO synthase blocker exhibited high
systemic BP, heavy proteinuria, further elevation of the ultrafil-
tration pressure with decreased Kf, and high incidence of FGS
after only eight weeks of treatment. Glomerular filtration and
perfusion were diminished and SNFF increased. Total RVR was
increased threefold, and proportional increases in RA and R
were observed. These observations accord well with previous
reports in both intact [15, 16] and remnant MW rats [40]. Finally,
hematocrit was increased in NAME-treated rats, which may have
contributed to the further elevation of systemic and glomerular
pressures, vascular resistances and concomitant glomerular injury
[4].
We observed that treatment with ACEI in UNX FHH rats
prevented the development of heavy proteinuria, which is other-
wise present in intact two-kidney FHH rats at comparable ages
and, in the current study, in UNX CON and NAME rats [41, 42].
The total proteinuria in NAME treated rats did not increase
above values found in controls. However, the reduction in GFR
may explain the lower UV. Indeed, when proteinuria is corrected
for GFR, one observes a greatly elevated protein excretion in
NAME-treated rats. Thus hydraulic permeability is diminished,
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while the permeability for protein is increased. Preliminary stud-
ies on the glomerular permselectivity indicated that the protein-
uria resulted mainly from changes in charge selectivity. Amelio-
ration of glomerular hypertension corrected this defect and
abolished proteinuria [38].
—
During the acute hemodynamic studies, MAP and P0 were
closely correlated. For each 10 mm Hg increase in MAP, P0c
increased by 3.3 mm Hg (Fig. 3). This is in contrast to values
found in two-kidney MW rats and UNX SHR rats, in which a 10
mm Hg systemic BP change led to P0 changes of 0.5 mm Hg [39]
and 1.0 mm Hg [43, 44], respectively. This may indicate that in
UNX FHH rats the mechanism to maintain constancy at P0 is
less effective, exposing the glomerular capillaries directly to
systemic BP variations, It remains to be determined, however,
whether observed P0 differences among groups are to some
extent due to suppression of the tubuloglomerular feedback
during stop-flow conditions or due to altered autoregulation as a
consequence of UNX [42]. Various reports suggest that the
endothelial NO synthase system and the renin-angiotensin system
interact as regulators of the glomerular microcirculation [45, 46].
Therefore, the NAME and ENA treated groups in our study
might represent the extremes of a continuum of activity of these
two systems combined. Any disturbance of the delicate balance in
the regulation of glomerular ultrafiltration might result in glomer-
ular malfunction.
Taken together, we demonstrated the importance of glomerular
hemodynamic alterations for the development of FGS, progres-
sive proteinuria, and CRF in this highly susceptible UNX FHH
model. By use of two different modulators of systemic BP and
consequently P0, we observed a strong association with glomer-
ular pressure and glomerular injury. Data on V0 in the current
study indicated that glomeruli in rats treated with ACEI re-
sponded to UNX with enlargement of the glomerular tuft, but this
process did not result in glomerular injury. Rats treated with
NAME had a lower V0, but showed a high incidence of sclerosis
after a follow-up of only eight weeks. These observations indicate
that changes in glomerular tuft size are poorly associated with the
formation of FGS in this model. Since the two-kidney FHH rat
develops FGS and uremia early in life, the 12 week follow-up after
UNX can be interpreted as a significant time in the life span of a
rat from this strain. We therefore believe that with the use of this
model in the current study, we allowed all measured pathophys-
iological mechanisms to be fully expressed. Our results strongly
suggest that the high intraglomerular pressure is the predominant
cause of proteinuria and FGS in the UNX FHH rat.
Acknowledgments
These studies were conducted with support from the Dutch Kidney
Foundation (C90.95.957A, A.P. Provoost) and the National Institutes of
Health (DK P01-40839, B.M. Brenner), and were presented in part at the
8th Scientific Meeting of the American Society of Hypertension (Am J
Hypertens 6:5A, 1993) and the 12th International Congress of Nephrology
(Abstract book:51, 1993). Enalapril was provided by Charles S. Sweet,
Ph.D. (Merck Sharp & Dohme Research Laboratories, West Point, PA).
The technical assistance of Miguel A. Zayas, Myriam Lee, Sandra T.
Downes, and Deborah J. Sandstrom is acknowledged.
Reprint requests to Abraham P. Provoost, Ph.D., Department of Pediatric
Surgety, Laborato,y for Surgeiy, Erasmus University, P.O. Box 1738, 3000
DR Rotterdam, The Netherlands.
References
1. BRENNER BM: Nephron adaptation to renal injury or ablation. Am J
Physiol 249:F324—F337, 1985
2. HOSTETTER TH, OLsON JL, RENNKE HG, VENKATACHALAM MA,
BRENNER BM: Hyperfiltration in remnant nephrons: a potentially
adverse response to renal ablation. Am J Physiol 241:F85—F93, 1981
3. ANDERSON 5, MEYER TW, RENNKE HG, BRENNER BM: Control of
glomerular hypertension limits glomerular injury in rats with reduced
renal mass. J C/in Invest 76:612—619, 1985
4. DL, ANDERSON 5, RENNKE HG, BRENNER BM: Anemia
lessens and its prevention with recombinant human erythropoietin
worsens glomerular injury and hypertension in rats with reduced renal
mass. Proc NatlAcad Sci USA 85:6142—6146, 1988
5. DWORKIN LD, BENSTEIN JA, PARKER M, TOLBERT E, FEINER HD:
Calcium antagonists and converting enzyme inhibitors reduce renal
injury by different mechanisms. Kidney mt 43:808—814, 1993
6. MEYER TW, ANDERSON S, RENNKE HG, BRENNER BM: Reversing
glomerular hypertension stabilizes established glomerular injury. Kid-
ney mt 31:752—759, 1987
7. NEURINGER JR, BRENNER BM: Hemodynamic theory of progressive
renal disease: a 10-year update in brief review. Am J Kidney Dis
22:98—104, 1992
8. DANIELS BS, HOSTETrER TH: Adverse effects of growth in the
glomerular microcirculation. Am J Physiol 258:F1409—F1416, 1990
9. YOSHIDA Y, KAWAMURA T, IK0MA M, FOGO A, ICHIKAWA I: Effects of
anti-hypertensive drugs on glomerular morphology. Kidney Int 36:
626—635, 1989
10. MILLER PL, RENNKE HG, MEYER TW: Glomerular hypertrophy
accelerates hypertensive glomerular injury in rats. Am J Physiol
261:F459—F465, 1991
11. KREISBERG JI, KARNOvSKY Mi: Focal glomerular sclerosis in the
fawn-hooded rat. Am J Pathol 92:637—652, 1978
12. PRovoosT AP, DE KEIJzER: The fawn-hooded rat: A model for
chronic renal failure, in Experimental and Genetic Models of Chronic
Renal Failure, edited by GRETZ N, STRAUCH M, Basel, Karger, 1993,
pp 100—1 14
13. SIMONs JL, PROVOOST AP, ANDERSON S, TROY JL, RENNKE HG,
SANDSTROM DJ, BRENNER BM: Pathogenesis of glomerular injury in
the fawn-hooded rat: early glomerular capillary hypertension predicts
glomerular sclerosis. JAm Soc Nephrol 3:1775—1782, 1993
14. SIMONS JL, PR0vO0ST AP, DE KEIJZER MH, ANDERSON 5, RENNKE
HG, BRENNER BM: Pathogenesis of glomerular injury in the fawn-
hooded rat: Effect of unilateral nephrectomy. J Am Soc Nephrol
4:1362—1370, 1993
15. BAYLIS C, MITRUKA B, DENG A: Chronic blockade of nitric oxide
synthesis in the rat produces systemic hypertension and glomerular
damage. J Cliii Invest 90:278—281, 1992
16. FUJIHARA CK, MICHELAZZO SM, SENA CR, PADILHA RM, S'iTOs
MM, DE Nucci G, ZATZ R: Massive albuminuria and renal paren-
chymal injury by chronic nitric oxide inhibition and salt overload.
(abstract) XIIth mt Congress Nephrol Abstracts 1993, p 52
17. BAYLIS C: Immediate and long-term effects of pregnancy on glomer-
ular function in the SHR. Am J Physiol 257:F1140—F1145, 1989
18. DEEN WM, TROY IL, ROBERTSON CR, BRENNER BM: Dynamics of
glomerular ultrafiltration in the rat. IV: Determination of the ultra-
filtration coefficient. J C/in Invest 52:100—1508, 1973
19. WEIBEL ER: Stereological Methods: Practical Methods for Biological
Morphometiy. London, Academic Press, 1979, pp. 51—57
20. VUREK GC, PEGRAM SE: Fluorometric method for the determination
of nanogram quantities of inulin. Anal Biochem 16:409—419, 1966
21. DAVIDSON WD, SACKNER MA: Simplification of the anthrone method
for the determination of inulin in clearance studies. J Lab Clin Med
62:35 1—356, 1963
22. CHASIS H, REDISH J, GOLDRING W, RAMGES HA, SMITH HW: Use of
sodium p-aminohippurate for functional evaluation of human kidney.
J Clin Invest 24:583—591, 1945
23. VIETS JW, DEEN WM, TROY JL, BRENNER BM: Determination of
serum protein concentration in nanoliter blood samples using fluores-
camine or o-ophthalaldehyde. Anal Biochem 88:513—521, 1978
24. MADDOX DA, DEaN WM, BRENNER BM: Glomerular filtration, in
Handbook of Physiology, edited by WINDHAGER EE, New York,
American Physiological Society, 1992, pp 545—638
404 Simons et a!: Modulation of glomerular hypertension and injuly
25. DWORKIN LD, FEINER HD: Glomerular injury in uninephrectomized
spontaneously hypertensive rats. A consequence of glomerular capil-
lary hypertension. J Clin Invest 77:797—809, 1986
26. LAFFERTY HM, BRENNER BM: Are glomerular hypertension and
"hypertrophy" indpendent risk factors for progression of renal dis-
ease? Semin Nephrol 10:294—304, 1990
27. WESTENEND PJ, NOOYEN JA, VAN DER KROGT JA, VAN BRUMMELEN
F, WEENING JJ: Functional and structural determinants of glomeru-
losclerosis in the fawn-hooded rat. EurJ Gun Invest 22:391—395, 1992
28. WE5TENEND PJ, NOOYEN JA, VAN DER KROGT JA, VAN BRUMMELEN
P, WEENING JJ: The effect of a converting enzyme inhibitor on renal
damage in spontaneously hypertensive fawn-hooded rats. J Hypertens
10:417—422, 1992
29. LAFAYETrE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II
receptor blockade limits glomerular injury in rats with reduced renal
mass. J Gun Invest 90:766—771, 1992
30. ANDERSON S. RENNKE HG, BRENNER BM: Nifedipine versus fosino-
pril in uninephrectomized diabetic rats. Kidney mt 41:891—897, 1992
31. PELAYO JC, QUAN AH, SHANLEY PF: Angiotensin II control of the
renal microcirculation in rats with reduced renal mass. Am J Physiol
258:F414—F422, 1990
32. YosHIoI T, SHIRAGA H, YOSHIDA Y, FoGo A, GLIcK AD, DEEN
WM, HOYER JR, IcHIIc.wA I: "Intact nephrons" as the primary origin
of proteinuria in chronic renal disease: Study in the rat model of
subtotal nephrectomy. J C/in Invest 82:1614—1623, 1993
33. Bioi AK, MITCHELL KO, SCHWARTZ MM, NAVAR LG, LEWIS EJ:
Absence of glomerular injury or nephron loss in a normotensive rat
remnant kidney model. Kidney Int 38:28—38, 1990
34. Iciiw I, HARRIS RC: Angiotensin actions in the kidney: Renewed
insight into the old hormone. Kidney mt 40:583—596, 1991
35. ITO S, ARIMA S, REN YL, JUNCOS LA, CARRETERO OA: Endothelium-
derived relaxing factor/nitric oxide modulates angiotensin II action in
the isolated microperfused rabbit afferent but not efferent arteriole. J
C/in Invest 91:2012—2019, 1993
36. BLANTZ RC, GABBAI FB, TUCKER BJ, YAMAMOTO T, WILSON CB:
Role of mesangial cell in glomerular response to volume and angio-
tensin II. Am J Physiol 264:F158—F165, 1993
37. AUKLAND K: Myogenic mechanisms in the kidney. J Hypertens 7
(Suppl 4):S71—S76, 1989
38. ICHIKAWA I, MIELE JF, BRENNER BM: Reversal of renal cortical
actions of angiotensin II by verapamil and manganese. Kidney mt
16:137—147, 1979
39. ZUSMAN RM: Effects of converting-enzyme inhibitors on the renin-
angiotensin-aldosterone, bradykinin, and arachidonic acid-prosta-
glandin systems: Correlation of chemical structure and biologic activ-
ity. Am J Kidney Dis 10 (Suppl 1):13—23, 1987
40. Fujia'it. CK, MICHELAZZO SM, SANTOS MM, DE NUCCI G, ZATZ R:
Chronic nitric oxide inhibition worsens glomerular injury in the
remnant kidney. (abstract) XIIth mt Congress Nephrol Abstracts 1993,
p 52
41. OLIvER JD, SIMONS JL, TROY JL, PROVOOST AP, BRENNER BM, DEEN
WM: Glomerular hypertension reduces charge selectivity in fawn
hooded rats. (abstract) JAm Soc Nephrol 3:746, 1992
42. PELAYO JC, WESTCOTr JY: Impaired autoregulation of glomerular
capillary hydrostatic pressure in the rat remnant nephron. J Gun Invest
88:101—105, 1991
43. DWORKIN LD, GROSSER M, FEINER HD, ULLIAN M, PARKER M: Renal
vascular effects of antihypertensive therapy in uninephrectomized
SHR. Kidney hit 35:790—798, 1989
44. DWORIUN LD, FEINER HD, PARKER M, TOLBERT E: Effects of
nifedipine and enalapril on glomerular structure and function in
uninephrectomized SHR. Kidney Int 39:1112—1117, 1991
45. O-iis-ii K, CARMINES PK, INSCHO EW, NAVAR LG: EDRF-angiotensin
II interactions in rat juxtamedullary afferent and efferent arterioles.
Am J Physiol 263:F900—F906, 1992
46. RAIJ L: Nitric oxide and the kidney. Circulation 87 (Suppl V):V26—
V29, 1993
